Rigetti Computing
Superconducting in a Trapped-Ion Library

Executive Summary

Rigetti is the public-market superconducting quantum-computing pure-play, the same modality IBM, Google and Amazon are building, but at 1/100th their R&D budget. The thesis is binary in a way IONQ's is not: either Rigetti carves out a credible architectural niche (custom tunable-coupler chip designs; modular multi-chip systems) and rides the NISQ-to-fault-tolerant transition, or it gets squeezed out as the incumbents commercialize. FY2024 revenue was just $10.8M², roughly one-tenth of IonQ's, and FY2025 revenue actually declined ~34% to $7.1M before re-accelerating in 2026 (Q2 CY26 $5.1M, +183% YoY); the trailing EV/Sales multiple still sits around 375× on TTM sales. The 108-qubit Cepheus-1 reached general availability on AWS Braket in April 2026 (the first >100-qubit system on Braket), superseding the older Ankaa line; the published roadmap now points to ~1,000 qubits at ~99.9% two-qubit fidelity over ~3 years. Our base-case discounted EV/Sales model implies ~$13 vs the $17 close, a clean-execution bull case supports ~$27, a bear case ~$5.

The Four Pillars of the Debate

Investment Thesis

The RGTI debate is binary on architecture and asymmetric on dilution. Rigetti has to either close the fidelity gap to trapped-ion and outflank the deep-pocketed superconducting incumbents (IBM Heron, Google Willow), or it gets squeezed into a research-vendor role. We frame three scenarios using a discounted EV/Sales model, RGTI is pre-profit, so a DCF is inappropriate.

Targets are the output of a simplified discounted EV/Sales model with subjective assumptions, illustrative, not analyst price targets. See sections 08 and 10 to adjust. Probability weights are symmetric 25/50/25 to reflect the high outcome dispersion characteristic of pre-profit deep-tech with both architectural and capital-structure tails.

Business Overview

Rigetti builds superconducting transmon quantum processors, the same fundamental modality as IBM, Google and Amazon's Ocelot, but with a differentiated focus on custom tunable-coupler chip designs and modular multi-chip "stitched" architectures. The thesis is that transmons win on raw gate speed (microseconds vs trapped-ion milliseconds) and on the manufacturability curve (standard semiconductor fab tooling), while custom couplers can close the fidelity gap that has historically favored trapped-ion.

The earlier product line was the Ankaa family: Ankaa-2 (84 qubits, ~98% median 2Q fidelity) went live in late 2023, and Ankaa-3 (84 qubits, ~99.5% median two-qubit) launched on Rigetti's Quantum Cloud Services platform in December 2024 and rolled out on AWS Braket and Microsoft Azure Quantum in early 2025. The current flagship is the 108-qubit Cepheus-1, which reached general availability on AWS Braket in April 2026 (the first >100-qubit system on Braket), superseding the previously-planned "Ankaa-4"; median fidelities are ~99.9% single-qubit and ~99.1% two-qubit, with 99.6–99.8% on smaller 36- and 9-qubit modules. The published roadmap now points to ~1,000 qubits at ~99.9% two-qubit fidelity over ~3 years via modular chip-stitching (a ~336-qubit step is a directional waypoint), the first systems at scale that would validate the "modular stitching" thesis vs IBM/Google monolithic-chip approaches.

The Architecture Trade-Off: Superconducting vs Trapped-Ion

Neither modality is "right", they are architectural bets on which engineering problem (fidelity vs scaling) gets solved first. Superconducting wins the fab game; trapped-ion wins the error-rate game. Rigetti is betting that as logical-qubit construction matures, fab scaling becomes the binding constraint.

Industry & Quantum Cycle

The quantum-computing sector is in the NISQ era (Noisy Intermediate-Scale Quantum, ~2024–2026): 100–2,000 physical qubits, limited error correction, very few production workloads. The gating milestone for the next phase is fault tolerance: the point at which logical qubits constructed from physical qubits can run arbitrarily long algorithms with bounded error. Google's Willow (2024) was the first below-threshold error-correction demonstration; IBM targets fault tolerance by 2029.

Within NISQ, four modalities compete in public markets and the labs. Superconducting (Rigetti, IBM, Google, Amazon Ocelot), fast gates, fab-friendly, fidelity-limited. Trapped-ion (IonQ, Quantinuum, Oxford Ionics), highest fidelity, slowest gates, hardest to scale physically. Neutral-atom (Atom Computing, Pasqal, QuEra), strong qubit-count scaling, mid-tier fidelity, room-temperature, optical traps. Photonic (PsiQuantum, Xanadu), room-temp, networkable, fidelity question marks for two-qubit gates.

The Competitive Set

The concentrated threat is IBM and Google. They share Rigetti's modality, can outspend it 100-to-1 on R&D, and have explicit roadmaps to fault tolerance. RGTI's defense is architectural specialization (tunable couplers, modular stitching) plus speed, but the moat is narrower than IonQ's modality-based one.

Where RGTI Sits in the Cycle

The Opportunity (TAM)

Quantum computing attacks problems classical machines cannot solve in tractable time, drug & materials discovery, optimization, logistics, finance, cryptography. The market is small today but inflecting: independent forecasters project the quantum-computing provider market growing from roughly $3.5B in 2025 to ~$20B by 2030 (~42% CAGR), with McKinsey estimating up to ~$72B of annual QC revenue by 2035 and BCG projecting $450–850B of cumulative economic value by 2040.

The TAM is identical to the one underwriting the IonQ thesis. What is different is the reasonable share-of-TAM Rigetti can claim. IONQ, with $130M of FY2025 revenue, $485M RPO, blue-chip enterprise customers and the only public trapped-ion brand, is plausibly underwriting 8–12% of quantum-provider dollars by 2030. Rigetti, with one-tenth the revenue base, a less-differentiated modality, and direct exposure to IBM/Google's superconducting roadmap, is more credibly modeled at 1–3% of TAM. That translates to ~$200–600M of 2030 revenue in the bull case, ~$40–120M in the base case, ~$15–40M in the bear case.

Financial Health

FY2024 GAAP revenue was $10.8M, and FY2025 revenue actually declined ~34% to $7.1M, the single most important number in the financials. Revenue is now re-accelerating off that tiny base: Q1 CY2026 came in at ~$4.4M and Q2 CY2026 at $5.1M (+183% YoY), roughly $9.5M for H1'26. The FY2025 GAAP net loss of ~$216M looks alarming until you separate the components: it is dominated by non-cash warrant / earn-out accounting that marks to market each quarter, and the non-GAAP net loss runs closer to ~$50M. Read the cash burn line, not the headline net loss.

The balance sheet is the cleanest part of the story. ~$541M cash & investments at Q2 CY26 with effectively no traditional debt, against a ~$60–80M operating cash burn rate, implies ~7 years of runway absent a raise. That fortress was built by a large 2025 ATM raise (~$347M during the late-2025 price spike) that lifted cash to ~$590M by year-end; it has since drifted down to ~$541M in H1'26 on operating burn (no H1'26 raise, only ~2M net new shares). So the dilution question is "when the next raise comes," not whether the balance sheet holds. The base case bakes in +15% further net dilution across the 2026→2030 window; the bear case +50%.

The cash position has narrowed the gap to the IonQ comp (~$541M vs ~$2.0B pro forma post-SkyWater, ~4× behind on absolute cash but no longer the dominant downside differentiator it was). On the burn ratio (cash / annual operating loss) RGTI now screens in line with IonQ: RGTI ~7 years vs IonQ ~6 years pro forma. The dilution math in section 08 is still material to the per-share fair-value calculation, but it is no longer the existential survival question it was when liquidity sat near $200M at the end of 2024, before the 2025 raise.

Cash Runway: Multi-Year, Defensive-Offensive Optionality

Bookings & Backlog

Rigetti does not report Remaining Performance Obligations the way IonQ does. The bookings picture has to be assembled from disclosed contract awards and program participation. The largest line is now a CHIPS Act letter of intent with the U.S. Dept. of Commerce, an award of up to $100M over three years. On DARPA's Quantum Benchmarking Initiative, RGTI completed Stage A (up to $1M, April 2025) but was NOT among the companies advanced to Stage B in the November 2025 cohort, an important negative vs the prior snapshot. Other identifiable government revenue: AFOSR research contracts (~$10–15M cumulative), Innovate UK / NQCC Harwell partnerships (Oxford Instruments collaboration; Quantum Missions Pilot with Riverlane), and DOE national-lab QPU placements.

Commercial revenue, primarily QPU access via AWS Braket, Microsoft Azure Quantum, and direct Rigetti Quantum Cloud Services, runs in the low single-digit-million-dollar range annually. We estimate roughly 70% of FY25 revenue is government-funded, with the balance from commercial cloud access. There is no enterprise customer of the IonQ-AstraZeneca caliber currently disclosed in the RGTI account list. That concentration matters because government revenue, while sticky once awarded, is exposed to appropriations cycles, and the failure to advance to DARPA QBI Stage B removes one leg of the forward pipeline.

Identifiable Contracts & Partners

Government concentration is sticky but appropriations-exposed. The commercial line, AWS Braket throughput and direct QCS subscriptions, is the variable the bull case needs to inflect. Watch it quarter to quarter; it is reported as a category but rarely broken out in dollar terms.

Valuation & Comps

RGTI trades at roughly 375× trailing (TTM) sales and ~277× FY26E sales. The multiple is eye-watering primarily because the denominator is so small, Rigetti's enterprise value of ~$4.98B is a normal-looking number for a deep-tech name with a credible 2030 roadmap; it is divided by ~$13M of trailing revenue that makes the headline ratio look broken. And FY2025 revenue actually declined, so the denominator got smaller before it grew.

The honest reframing is the forward-2030 multiple. At the base-case ~$500M 2030 revenue and a 15× exit EV/Sales, the implied 2030 enterprise value is ~$7.5B, and discounting it back four years at 14% with +15% net dilution lands on ~$13/share, vs the current $17 close. The bull case ($750M at 19.5×, +8% dilution, 12% WACC) takes that to ~$27; the bear ($380M at 10×, +50% dilution, 18% WACC) to ~$5. That is the EV/Sales-compression chart on the summary page in plain language.

Versus IONQ, the closest direct comp, RGTI's trailing multiple (~375×) is materially richer than IONQ's (~109×) because the revenue base is a fraction the size. On forward 2030E base, the two compress: RGTI to ~10× ($4.98B EV / $500M base 2030 revenue); IONQ to ~16× in our IONQ base scenario.

Valuation Model: Discounted EV/Sales

Pick a ~2030 revenue, an exit EV/Sales multiple, a discount rate and net dilution; the model discounts the implied future enterprise value back four years, adds net cash, and divides by diluted shares. The dilution slider still matters, Rigetti funds operations through ATM programs, but the ~$541M Q2 CY26 cash position means the base case can be funded with only +15% further net dilution across the 2026→2030 window. Use the presets, then move the sliders.

Revenue Ramp & Implied EV ($M)

Sensitivity: Implied Price ($)

Catalysts & Roadmap

Roadmap Milestones

Scenario Targets

This calculator uses the same discounted EV/Sales math at a fixed 14% WACC and 4-year horizon. Move the inputs to see the implied price and a rough scenario-likelihood read. The dilution range still spans 0–80% across the model window, RGTI's ATM history makes dilution path the single biggest swing factor even with the ~$541M cash buffer.

Bull vs Bear

Technicals & Positioning

RGTI is among the most volatile equities in the quantum cohort. The 52-week range, $12.53 to $58.15: is anchored by the late-'24/early-'25 quantum-sector rally (Google Willow Dec '24, Microsoft Majorana 1 Feb '25) that carried into a Q3-Q4 2025 momentum peak around $58 in mid-October 2025, before mean-reverting into the teens through 2026. At $17 the stock sits well off the high, ~72% below its 52-week high.

Short interest typically runs 18–25% of the float: meaningfully heavier than IONQ, reflecting both the smaller market cap (easier to borrow against) and the structural dilution thesis. That short positioning cuts both ways: it amplifies downside on negative milestones and equity-raise announcements, but it sets up sharp short-squeeze rallies on positive surprises (a Cepheus fidelity beat, a CHIPS Act award, a sector-wide quantum re-rate).

Risk / Reward Tool

Note: The assistant reasons from the dashboard's data snapshot and thesis sections, it does not browse the web or access real-time fundamentals beyond what's in data.js. Treat its responses as scenario-modeling support, not as primary research.

Risks